To contribute to the debate about the minimum hospital volume of radical cystectomies (RCs) by estimating the association between hospital volume (HV) and postoperative mortality. Patients who underwent a RC for bladder cancer between January 1st, 2008 and December 31st , 2018 were retrospectively identified from the Netherlands Cancer Registry.
To evaluate the possible major adverse cardiovascular events (MACE) associated with second-line hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). We performed a population-based real-world cohort study of 4962 prostate cancer patients between 2014 and 2017 utilizing the Chang Gung Research Database of Taiwan.
Purpose: Prostate cancer (PCa) is the most common solid organ cancer and second leading cause of death in men. Multiparametric magnetic resonance imaging (mpMRI) enables detection of the most aggressive, clinically significant PCa (csPCa) tumors that require further treatment.
To investigate men’s experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial. A longitudinal qualitative interview study was embedded in the ProtecT RCT.
This study aimed to determine whether the addition of transperineal systematic biopsies (SB) to targeted biopsies (TB) improved clinically significant prostate cancer (csPC) detection rates without high increase in insignificant prostate cancer detection rates in an Australian population.
Prostate cancer is the second most common and the sixth deadliest male cancer worldwide.1 In the UK, 43% of men present with low- and intermediate-risk localised disease,2 for which level 1 evidence suggests non-inferiority of active surveillance (AS) to radical treatment in terms of 10-year survival.3,4
Over the last 10 years, advances in technology and efforts to improve cost-effectiveness have allowed many endourological procedures to no longer require hospital admission. The benefits of outpatient surgery include cost savings for the health care system and reduced morbidity for the patient.1 The endoscopic management of ureteral and kidney stones on an outpatient basis […]
Dr. Veeru Kasivisvanathan (GB, centre) receives the EAU Prostate Cancer Research Award at EAU19 in Barcelona. The European Association of Urology (EAU) relentlessly pursues its mission of raising the level of urological care throughout Europe and beyond. High-quality research conducted by urologists, urologists-in-training, and scientists is vital to this mission. To honour members with significant contributions […]
To develop an international consensus on managing penile cancer patients during the COVID-19 acute waves. A major concern for patients with penile cancer during the coronavirus disease 2019 (COVID-19) pandemic is how the enforced safety measures will affect their disease management.
While the majority of patients with advanced testicular germ cell tumors (GCT) achieve complete responses after chemotherapy and if indicated after postchemotherapy resection of residual lesions, about 20% of patients have incomplete responses or show relapses.
